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Abstract 
Under the concept of "Industry 4.0", production processes will be pushed to be increasingly interconnected, 
information based on a real time basis and, necessarily, much more efficient. In this context, capacity optimization 
goes beyond the traditional aim of capacity maximization, contributing also for organization’s profitability and value. 
Indeed, lean management and continuous improvement approaches suggest capacity optimization instead of 
maximization. The study of capacity optimization and costing models is an important research topic that deserves 
contributions from both the practical and theoretical perspectives. This paper presents and discusses a mathematical 
model for capacity management based on different costing models (ABC and TDABC). A generic model has been 
developed and it was used to analyze idle capacity and to design strategies towards the maximization of organization’s 
value. The trade-off capacity maximization vs operational efficiency is highlighted and it is shown that capacity 
optimization might hide operational inefficiency.  
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1. Introduction 
The cost of idle capacity is a fundamental information for companies and their management of extreme importance 
in modern production systems. In general, it is defined as unused capacity or production potential and can be measured 
in several ways: tons of production, available hours of manufacturing, etc. The management of the idle capacity 
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Abstract 
Microneedles (MN) skin patches are novel medical devices in micron scale with a needle array which offers an alternative drug 
delivery system to conventional methods. MN patches are applied onto the skin reaching the dermal layer where the drug 
molecules are released at a specific rate. There is a lack of knowledge surrounding some determinant factors required to define an 
efficient MN application into the user skin. The aim of the project is to determine the optimum application parameters to 
fabricate a polymeric MN patch and to design a disposable single-use MN applicator with enhanced usability. 
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1. Introduction 
The aim of the project is to develop a dissolvable microneedle (MN) patch integrated with a mechanical 
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This robust integrated patch will provide accurate and consistent control of insertion depth irrespective of 
different application rates, application forces and moreover, different thumb or finger sizes thereby, minimising 
operational errors.  The overall purpose of the project is to improve the patient compliance with this novel drug 
delivery application system.  Therefore, the key objectives of this project are: 
 
1. Fabrication and characterization of polymeric MN using spray technology already established in Cork 
Institute of Technology (CIT)/University College Cork (UCC) research group (Ireland). 
2. Assess the effect of process conditions and sterilisation on the MN properties.   
3. Establish the key parameters that contribute to efficient and consistent insertion of MN. 
4. Design and develop a low cost single use applicator that eliminates inconsistencies associated with manual 
application. 
5. Integrate the applicator and MN array into a single unit, taking factors such as fabrication, sterilisation, use 
and disposal into consideration. 
6. Test prototypes of the new applicator design and compare its performance with manual and existing multi-
use applicator designs to establish which insertion technique enables the most reliable self-application of MN arrays. 
This study briefly summarises the methodology of the proposed work and also reviews key elements of the 
project. The key project elements includes: MN overview, materials selection, MN design and fabrication process, 




GPa        GigaPascals 
MPa       MegaPascals 
kGy KiloGray 
m/s Meters per second 
pJ/μm2 PicoJules per square micrometres 
2. Methodology 
The project will involve the fabrication of polymeric microneedle patches by atomized spray technology, 
characterization of MN under different conditions and processes, the integration of both MN patch and applicator, 
their validation and verification so as to construct and perform testing of the prototype based on the proposed design. 
The proposed MN patch system will consist of two integrated parts: 1) a dissolvable MN layer constructed from 
poly-lactic-glycolic-acid (PLGA) which will be of suitable mechanical strength to breach the stratum corneum (SC) 
and 2) an applicator which will be built into the backing of the MN layer to provide an effective and controlled 
application.  Each polymeric MN patch composed of PLGA will be fabricated by applying the polymer onto poly-
dimethylsiloxane (PDMS) moulds using atomized spraying technology. PDMS moulds are provided by Tyndall 
Institute in UCC.  Relevant factors for the optimisation of the fabrication process, such as nozzle height, flow rate, 
polymer concentration, polymer type will be assessed due to their influence on the physical and mechanical 
properties of PLGA. The MN will be sterilised using gamma radiation with a dose of 29.1-29.7 kGy, adhering to 
U.S. Food and Drug Administration (FDA) guidelines (BS EN 556-2:2015). The effects of sterilisation on the 
physiochemical and mechanical properties will be analysed by different characterization techniques. The design of 
the MN applicator will involve different phases, starting with the study of the influence of the MN geometry on the 
insertion force, fracture/buckling failure forces and other factors that influence the MN performance. Using Finite 
Element Analysis modelling (FEA), skin and MN behaviours will be predicted so as to optimise insertion parameters 
and needle array parameters such as array density, base plate diameter and the resulting insertion force. Computer-
Aided Design (CAD) modelling will facilitate design of an optimised MN applicator and visualise the integrated 
system before manufacturing of the parts. The applicator design will follow the current regulations, such as FDA 
regulations and EU regulations (MEDDEV regulations) that classify the potential designs as a Class IIa or IIb device 
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This robust integrated patch will provide accurate and consistent control of insertion depth irrespective of 
different application rates, application forces and moreover, different thumb or finger sizes thereby, minimising 
operational errors.  The overall purpose of the project is to improve the patient compliance with this novel drug 
delivery application system.  Therefore, the key objectives of this project are: 
 
1. Fabrication and characterization of polymeric MN using spray technology already established in Cork 
Institute of Technology (CIT)/University College Cork (UCC) research group (Ireland). 
2. Assess the effect of process conditions and sterilisation on the MN properties.   
3. Establish the key parameters that contribute to efficient and consistent insertion of MN. 
4. Design and develop a low cost single use applicator that eliminates inconsistencies associated with manual 
application. 
5. Integrate the applicator and MN array into a single unit, taking factors such as fabrication, sterilisation, use 
and disposal into consideration. 
6. Test prototypes of the new applicator design and compare its performance with manual and existing multi-
use applicator designs to establish which insertion technique enables the most reliable self-application of MN arrays. 
This study briefly summarises the methodology of the proposed work and also reviews key elements of the 
project. The key project elements includes: MN overview, materials selection, MN design and fabrication process, 
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2. Methodology 
The project will involve the fabrication of polymeric microneedle patches by atomized spray technology, 
characterization of MN under different conditions and processes, the integration of both MN patch and applicator, 
their validation and verification so as to construct and perform testing of the prototype based on the proposed design. 
The proposed MN patch system will consist of two integrated parts: 1) a dissolvable MN layer constructed from 
poly-lactic-glycolic-acid (PLGA) which will be of suitable mechanical strength to breach the stratum corneum (SC) 
and 2) an applicator which will be built into the backing of the MN layer to provide an effective and controlled 
application.  Each polymeric MN patch composed of PLGA will be fabricated by applying the polymer onto poly-
dimethylsiloxane (PDMS) moulds using atomized spraying technology. PDMS moulds are provided by Tyndall 
Institute in UCC.  Relevant factors for the optimisation of the fabrication process, such as nozzle height, flow rate, 
polymer concentration, polymer type will be assessed due to their influence on the physical and mechanical 
properties of PLGA. The MN will be sterilised using gamma radiation with a dose of 29.1-29.7 kGy, adhering to 
U.S. Food and Drug Administration (FDA) guidelines (BS EN 556-2:2015). The effects of sterilisation on the 
physiochemical and mechanical properties will be analysed by different characterization techniques. The design of 
the MN applicator will involve different phases, starting with the study of the influence of the MN geometry on the 
insertion force, fracture/buckling failure forces and other factors that influence the MN performance. Using Finite 
Element Analysis modelling (FEA), skin and MN behaviours will be predicted so as to optimise insertion parameters 
and needle array parameters such as array density, base plate diameter and the resulting insertion force. Computer-
Aided Design (CAD) modelling will facilitate design of an optimised MN applicator and visualise the integrated 
system before manufacturing of the parts. The applicator design will follow the current regulations, such as FDA 
regulations and EU regulations (MEDDEV regulations) that classify the potential designs as a Class IIa or IIb device 
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depending on how long the MN patch takes to dissolve in the skin and if the applicator will remain with the MN 
patches after application. Finally, validation and verification of the integrated system will be done so as to ensure its 
effective usability, where ex-vivo pig skin studies will be performed in UCC. A variety of software packages will be 
used in this project: CES Edupack will be used to research into materials and their properties; FEA modelling will be 
performed with Abaqus and CAD modelling with SolidWorks and Abaqus; statistical analysis will be performed 
using Minitab, SPSS and Gpower. 
3. Project review 
3.1. Microneedle overview 
MN skin patches are novel medical devices consisting of an array of needles less than 2 mm in height. MN 
mediated transdermal delivery is an interesting route of administration for the systemic delivery of drugs and offers 
an alternative approach compared to the conventional parenteral methods. Conventional drug delivery methods such 
as intravenous (IV), intramuscular (IM), and subcutaneous, sublingual (SD) administration are used extensively in 
medical practice, with an estimated 16 billion injections administered worldwide in IV drug administration. Despite 
efficacy and worldwide use, IV, IM and subcutaneous drug delivery systems are associated with patient pain, 
phobia, anxiety, hazardous waste and needle pricks across adult and pediatric populations alike [6,7] . Medicated 
MN patches are presented as an alternative to the complications associated with hypodermic needles. Delivering 
pharmacological molecules in a minimally invasive manner by applying the medicated patch to the skin, this method 
offers an effective delivery system which is pain-free, biologically safe without biohazard waste, patient friendly 
and self-directed in its application. Other important considerations include avoidance of the harsh gastrointestinal 
problems (pH, enzymatic degradation, hepatic metabolism) with using this systemic delivery system and long term 
storage with the avoidance of long cold storage trains [8]. Therefore, from an ethical perspective, MN are a desirable 
option. 
3.2. Microneedle design 
There are four main MN types; solid, coated, dissolvable and hollow MN as can be seen in Fig. 1. Solid MN 
create micropores from their application to the skin which is subsequently followed by applying a drug solution 
layer where the formulation enters the temporary formed pores [3]. This mode of action is referred to as “poke and 
patch”.  Coated MN are solid MN coated with the drug. The drug dissolves from the solid MN into the skin and the 
solid MN are removed from the skin (“coat and poke” approach).  Dissolving MN are made from biodegradable 
materials which dissolve in the skin releasing the drug. This is termed a “poke and release” method. Finally, hollow 
MN are similar to conventional hypodermic needles but shorter in length where the drug liquid formulation is 
injected into the skin (“poke and flow” approach).  
Fig. 1. Different types of micro-needle design [3].  
 
Fig 2. (a). An estimation of mean epidermal cell nuclei of 8.6 
microns [10]; (b) Comparison between conventional 
intramuscular injection by hypodermic needle and MN. 
[11].
All MN patches, irrespective of the MN type, are applied onto the outer layer of the skin, the epidermis. It is 
composed by keratinocytes, melanocytes, Langerhans cells and Merkel cells. As an overview of the epidermis, it is 
divided in 5 or 4 layers depending on the part of the body: SC, stratum lucidum, stratum granulosum, stratum 
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spinosum, and stratum basale. The MN patches work by breaching the SC, which is composed of 10 to 30 layers of 
flattened corneocytes (10-20 microns in depth), which are mostly lipid secretions and keratin. The main function of 
the SC is to act as a repellent barrier or to regulate water level in the body, protecting deeper layers from microbial 
infection and mechanical and chemical stresses. An illustration of skin layer can be seen in Fig. 2. The MN structure 
penetrates this epidermis layer, and then the upper layers of the dermis, second skin layer, without reaching the 
abundant amount of pain sensitive nerve endings. These nerve endings are mechanoreceptors and thermoreceptors 
with the primary aim to provide the sense of touch and heat, and they are responsible of the sensation of pain. The 
dermis layer is located approximately 40 microns from the skin surface and is also where the blood capillary system 
lies which is responsible for transporting the drug around the body. According to some studies, the Young Modulus 
of the skin varies between 4.6 MPa and 20 MPa for mechanical tests, but this factor is dependent of the age, and it 
affects the insertion force of a MN into the skin. This same study explains that the skin stretching decreases almost 4 
MPa from one neonate to an elderly adult, the same effect can be seen for the elasticity modulus, reducing from 70 
MPa in a child to 60 MPa in an elderly adult [9]. Skin parameters will be evaluated in order to build a valid FEA 
model that represents the intended target population.  Findings of current MN patches studies will be investigated in 
order to understand the factors that determine the optimal conditions for insertion into the skin, such as needle 
height, tip radius, base diameter, needle angle and array density. Extensive research has been performed 
investigating different MN heights. MN heights in the range of 500-600 microns have been found to be optimal 
reducing pain, bleeding and possibility of infection [3, 13]. Also, it has been found that microneedle insertion is 
facilitated with smaller tip diameters, bigger distance between MN in the MN array, and the octagonal pyramidal 
MN shape, and is independent on the number of needles in the patch [14,15,16].In this study, dissolvable MN in the 
range of 500-600 microns will be fabricated. 
3.3. Microneedle material 
Solid MN are mainly made of metal, silicon, ceramic or polymers. However, biodegradable materials such as 
polymers, sugars and more recently bioceramics can be employed to fabricate the dissolving microneedle structures. 
The drug is formulated into the biodegradable material [17]. In this study, the material selected for construction of 
the MN is PLGA, what is a copolymer composed of lactic and glycolic acid repeat units. PLGA is a FDA approved 
material which is non-toxic, biocompatible and safe to use. PLGA is commonly used in the biomedical field for 
sutures, fracture fixation, oral implants and drug-delivery due to its diverse properties. Some of the physical 
properties associated with PLGA can be seen in Table I. The physical properties of PLGA can change depending on 
the initial molecular weight (MW), lactic-glycolic acid ratio (LA:GA), size of the device, exposure to water (surface 
shape) and storage temperature.  PLGA typically has an amorphous structure with disordered polymer chains. The 
glass transition temperature (Tg) ranges from 45 to 55 ºC. It is dependent on the lactic acid content and on the 
degradation time, and it is dependent on the copolymer composition as well as on the MW.  However, there are 
some semi-crystalline PLGA materials, with 35-55% crystallinity. The Tg will influence the mechanical strength of 
the polymer and also, the stability of the material on storage. The Young Modulus for the PLGA is 2GPa with 3-10 
% polymer elongation (tensile properties) and it is almost a constant with independence of the LA:GA ratio, and Tg.  
Also, the MW and polydispersity index can affect the mechanical strength of the material, but LA:GA ratio does not 
affect the mechanical strength, nor elongation, but it does have an effect in the degradation time and in the Tg.  
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depending on how long the MN patch takes to dissolve in the skin and if the applicator will remain with the MN 
patches after application. Finally, validation and verification of the integrated system will be done so as to ensure its 
effective usability, where ex-vivo pig skin studies will be performed in UCC. A variety of software packages will be 
used in this project: CES Edupack will be used to research into materials and their properties; FEA modelling will be 
performed with Abaqus and CAD modelling with SolidWorks and Abaqus; statistical analysis will be performed 
using Minitab, SPSS and Gpower. 
3. Project review 
3.1. Microneedle overview 
MN skin patches are novel medical devices consisting of an array of needles less than 2 mm in height. MN 
mediated transdermal delivery is an interesting route of administration for the systemic delivery of drugs and offers 
an alternative approach compared to the conventional parenteral methods. Conventional drug delivery methods such 
as intravenous (IV), intramuscular (IM), and subcutaneous, sublingual (SD) administration are used extensively in 
medical practice, with an estimated 16 billion injections administered worldwide in IV drug administration. Despite 
efficacy and worldwide use, IV, IM and subcutaneous drug delivery systems are associated with patient pain, 
phobia, anxiety, hazardous waste and needle pricks across adult and pediatric populations alike [6,7] . Medicated 
MN patches are presented as an alternative to the complications associated with hypodermic needles. Delivering 
pharmacological molecules in a minimally invasive manner by applying the medicated patch to the skin, this method 
offers an effective delivery system which is pain-free, biologically safe without biohazard waste, patient friendly 
and self-directed in its application. Other important considerations include avoidance of the harsh gastrointestinal 
problems (pH, enzymatic degradation, hepatic metabolism) with using this systemic delivery system and long term 
storage with the avoidance of long cold storage trains [8]. Therefore, from an ethical perspective, MN are a desirable 
option. 
3.2. Microneedle design 
There are four main MN types; solid, coated, dissolvable and hollow MN as can be seen in Fig. 1. Solid MN 
create micropores from their application to the skin which is subsequently followed by applying a drug solution 
layer where the formulation enters the temporary formed pores [3]. This mode of action is referred to as “poke and 
patch”.  Coated MN are solid MN coated with the drug. The drug dissolves from the solid MN into the skin and the 
solid MN are removed from the skin (“coat and poke” approach).  Dissolving MN are made from biodegradable 
materials which dissolve in the skin releasing the drug. This is termed a “poke and release” method. Finally, hollow 
MN are similar to conventional hypodermic needles but shorter in length where the drug liquid formulation is 
injected into the skin (“poke and flow” approach).  
Fig. 1. Different types of micro-needle design [3].  
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spinosum, and stratum basale. The MN patches work by breaching the SC, which is composed of 10 to 30 layers of 
flattened corneocytes (10-20 microns in depth), which are mostly lipid secretions and keratin. The main function of 
the SC is to act as a repellent barrier or to regulate water level in the body, protecting deeper layers from microbial 
infection and mechanical and chemical stresses. An illustration of skin layer can be seen in Fig. 2. The MN structure 
penetrates this epidermis layer, and then the upper layers of the dermis, second skin layer, without reaching the 
abundant amount of pain sensitive nerve endings. These nerve endings are mechanoreceptors and thermoreceptors 
with the primary aim to provide the sense of touch and heat, and they are responsible of the sensation of pain. The 
dermis layer is located approximately 40 microns from the skin surface and is also where the blood capillary system 
lies which is responsible for transporting the drug around the body. According to some studies, the Young Modulus 
of the skin varies between 4.6 MPa and 20 MPa for mechanical tests, but this factor is dependent of the age, and it 
affects the insertion force of a MN into the skin. This same study explains that the skin stretching decreases almost 4 
MPa from one neonate to an elderly adult, the same effect can be seen for the elasticity modulus, reducing from 70 
MPa in a child to 60 MPa in an elderly adult [9]. Skin parameters will be evaluated in order to build a valid FEA 
model that represents the intended target population.  Findings of current MN patches studies will be investigated in 
order to understand the factors that determine the optimal conditions for insertion into the skin, such as needle 
height, tip radius, base diameter, needle angle and array density. Extensive research has been performed 
investigating different MN heights. MN heights in the range of 500-600 microns have been found to be optimal 
reducing pain, bleeding and possibility of infection [3, 13]. Also, it has been found that microneedle insertion is 
facilitated with smaller tip diameters, bigger distance between MN in the MN array, and the octagonal pyramidal 
MN shape, and is independent on the number of needles in the patch [14,15,16].In this study, dissolvable MN in the 
range of 500-600 microns will be fabricated. 
3.3. Microneedle material 
Solid MN are mainly made of metal, silicon, ceramic or polymers. However, biodegradable materials such as 
polymers, sugars and more recently bioceramics can be employed to fabricate the dissolving microneedle structures. 
The drug is formulated into the biodegradable material [17]. In this study, the material selected for construction of 
the MN is PLGA, what is a copolymer composed of lactic and glycolic acid repeat units. PLGA is a FDA approved 
material which is non-toxic, biocompatible and safe to use. PLGA is commonly used in the biomedical field for 
sutures, fracture fixation, oral implants and drug-delivery due to its diverse properties. Some of the physical 
properties associated with PLGA can be seen in Table I. The physical properties of PLGA can change depending on 
the initial molecular weight (MW), lactic-glycolic acid ratio (LA:GA), size of the device, exposure to water (surface 
shape) and storage temperature.  PLGA typically has an amorphous structure with disordered polymer chains. The 
glass transition temperature (Tg) ranges from 45 to 55 ºC. It is dependent on the lactic acid content and on the 
degradation time, and it is dependent on the copolymer composition as well as on the MW.  However, there are 
some semi-crystalline PLGA materials, with 35-55% crystallinity. The Tg will influence the mechanical strength of 
the polymer and also, the stability of the material on storage. The Young Modulus for the PLGA is 2GPa with 3-10 
% polymer elongation (tensile properties) and it is almost a constant with independence of the LA:GA ratio, and Tg.  
Also, the MW and polydispersity index can affect the mechanical strength of the material, but LA:GA ratio does not 
affect the mechanical strength, nor elongation, but it does have an effect in the degradation time and in the Tg.  











glycolide) 85/15 2.0 3-10 
Ethyl acetate, chloroform, 
acetone, THF Amorphous 5-6 
Interference screws, suture 
anchors, ACL reconstruction 
Poly(D,L-lactide-co-
glycolide) 75/25 2.0 3-10 
Ethyl acetate, chloroform, 
acetone, DMF, THF Amorphous 4-5 
Plates, mesh, screws, tack, 
drug delivery 
Poly(D,L-lactide-co-
glycolide) 50/50 2.0 3-10 
Ethyl acetate, chloroform, 
acetone, DMF, THF Amorphous 1-2 
Orthopedic implants, drug 
delivery 
Poly(L-lactide-co-
glycolide) 10/90 -      
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These are important characteristics which have implications for the application of the MN into the skin to ensure 
that the MN did not break on impact. PLGA is biodegradable through the hydrolysis of its ester bonds along the 
backbone forming labile by-products (alcohols and acids) which can be easily metabolised in the body. The 
degradation kinetics of the polymers is dependent on the lactic-glycolic acid ratio and the molecular weight. 
Therefore, the drug release can be tailored (over 1-6 months) as a result on the chemical composition of the 
copolymer selected. The material can encapsulate molecules of virtually any size such as chemical and protein 
drugs. PLGA is a polymer that can be easily processed e.g. solvent casting and thermal processing methods. The 
polymer can cast into any shape using solvents such as chlorinated solvents, tetrahydofuran, acetone and ethyl 
acetate [18, 19]. Understanding the properties of PLGA is important in order to select the right copolymer for this 
study: PLGA is an attractive material and it is a perfect candidate for the fabrication of MN for transdermal use as a 
result of its mechanical, biodegradation and casting characteristics, as it has been shown in recent studies [17]. Chen 
et al. have fabricated successfully MNs patches composed of embeddable chitosan MN and poly(L-lactide-co-D,L-
lactide) (PLA) as a supporting array for the delivery of encapsulated antigens to the skin, being a proper material for 
this purpose [20]. 
3.4. Fabrication process 
A wide range of MN fabrication processes have been researched. These include micro moulding, thermal 
drawing, injection moulding process, centrifugation [3, 21, 22]. In this study, the dissolving MN will be fabricated 
by micro-moulding methods. Moulds are fabricated using a hydrophobic material, PDMS.  The process for 
preparing the moulds involves pouring a PDMS solution over a master structure coated with platinum and then by 
curing the polymer overnight at room temperature. Once moulds are cured, they are peeled from the master 
structures and used as master structures for the creation of MN patches [3]. The polymeric MN will be prepared 
using an atomized spray technique. Recent studies demonstrated that MN can be fabricated with polymeric materials 
creating an amorphous content using single formula sugars, with either a novel laminate-layered or horizontally-
layered dissolving MN arrays, by adapting the spraying method [21]. Polymeric MN have been already fabricated 
by CIT’s research group being orthogonal shaped MN with sharp tips. 
3.5. Sterilisation 
Sterilisation of the prototype is an important consideration. McCrudden et al. studied the considerations in the 
sterile manufacture of hydrogel MN arrays with some model drugs. Results showed that no measurable bioburden 
was detected in any of the prepared devices and endotoxin levels were below the FDA limits (20 endotoxin 
units/device). The hydrogel-forming MN were not affected by gamma irradiation (25 kGy) in terms of their physical 
properties or drug capabilities. However, sterilisation process decreased the drug concentration of the MN patches 
[23]. In this study, the PLGA MN will be sterilised according to the FDA guidelines using gamma radiation. The 
effect of the sterilisation process on the polymer characteristics will be studied and new routes of approach may be 
taken. 
3.6. Applicator design 
To allow a reproducible and repeatable delivery of the drug, MN should be inserted into the skin in a controlled 
and reproducible manner. This demands the use of an applicator such as a manual (thumb pressure actuator or 
applicator system) or mechanical (spring-loaded mechanism or piston driven) system which is either for a single use 
or multiple use [17]. Our research will focus in the design and building of a MN applicator which will be integrated 
into the MN backing layer.  An investigation into the relevant key factors for the clinical use of MN patches (with or 
without applicator) must be considered as these are an important part of the established regulatory requirements, 
these includes [8]: 1) Effective, uniform and repeatable MN application to overcome any variations in skin 
properties; 2) Controlled depth of penetration of the MN into the skin so as to prevent introduction of microbial 
contamination and to avoid potential infections; 3) Sufficient mechanical strength to breach the SC without 
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fracturing the MN structures on the patch; 4) Easy and safe to use as well as being pain-free if an applicator is 
utilised [17]; 5) Ease of sterilisation; and 6) Maintain proper physical stability and physical integrity during storage 
and application. There are several designs commercially available for the use of solid or hollow MN only (3M, 
Zosano® Pharma, MicroCor™, Adminpatch®, Micronjet®, BD Soluvia™, MTS-Rollers™, see in Fig. 3.) but 
commercial applicators for the administration of dissolvable MN are not available at the moment. It has been shown 
that manual impact insertion devices result in low penetration efficiencies (56%) with high inter and intra-individual 
variation compared to mechanical impact insertion devices. This was attributed to the variations in applied force 
which were below optimum insertion conditions [5].  This supports the need for an applicator device to assist in the 
insertion of the MN patch. However, it must also be noted that there are a number of disadvantages associated with 
existing applicators for solid and hollow MN such as: 1) additional application system required by the patch; 2) 
large cumbersome and awkward devices; 3) re-sterilisation for multiple use; 4) risk of infections and 5) clogging of 
MN in the case of hollow MN in its re-use. There are also other designs currently under research that include 
vibration and electrical driven mechanisms [25]. The use of thumb pressure actuation directly onto the base plate of 
the MN patch is complex and with high inter and intra-individual variability. Electrical driven devices which 
possess adjustable forces are more stable over time and more suitable for multiple use compared to manual or spring 
induced forces [25].  However, for single use, a mechanical driven applicator could be better from an economic 
point of view. In the last year, there were publications proving the effective use of integrated systems (built-in 
insertion mechanism into each patch) which are designed with spring loaded mechanism, with two concentric rings, 
and a push-plate, for solid MN with the intended use of penetrating different skin models in one-handling step [2]. 
This proof-of-concept study ascertained that their integrated applicator-assisted insertion method resulted in 80% 
penetration efficiency on a foam material (skin model) compared to manual applicator methods due to the force 
distribution onto the pushing plate and that the puncture efficiency has a factor three times higher when applying 
thumb pressure on the patch base plate directly.  
 
         
Fig 3. MN applicators from different companies. (a) MicroCor™ applicator; (b) Zosano's Macroflux®; (c) AdminPatch®; (d) MicronJet®;         
(e) BD Soluvia™ .Adapted from BD (2009); (f) MTS-Rollers™ applicator. (Adapted for review publication [24]. 
 
The same study also showed that the use of an impact-insertion applicator improves the efficiency and 
reproducibility for a high-density MN path. In this study, spring loaded and push-plate mechanisms will be 
investigated. The applicator and its parts can be fabricated with methods such as 3D printing, plastic injection, or 
with conventional machining, all available in CIT. 
3.7. Characterisation methods 
In order to characterise the fabricated polymeric MN and to set the applicator specifications, the methods used 
will include a qualitative scoring system, imaging using optical light microscopy and scanning electron microscopy 
(SEM) and some methods to determine the physical and structural features of the patches (the shape, size and 
number of micro-needles produced on a patch). Chemical analyses will determine the chemical structure (Raman 
spectroscopy) and the chemical phases present (crystalline/amorphous (differential scanning calorimetry (DSC)). 
The mechanical properties (tensile strength and compression) will be determined using an Instron Dynamic testing 
machine. Also a number of artificial skin models will be examined by using ex-vivo pig skin studies in order to 
understand the influence of MN geometry and applied force versus penetration depth. It is important to note that 
CIT research team in collaboration with UCC have developed expertise in the area of drug delivery, in particular 
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These are important characteristics which have implications for the application of the MN into the skin to ensure 
that the MN did not break on impact. PLGA is biodegradable through the hydrolysis of its ester bonds along the 
backbone forming labile by-products (alcohols and acids) which can be easily metabolised in the body. The 
degradation kinetics of the polymers is dependent on the lactic-glycolic acid ratio and the molecular weight. 
Therefore, the drug release can be tailored (over 1-6 months) as a result on the chemical composition of the 
copolymer selected. The material can encapsulate molecules of virtually any size such as chemical and protein 
drugs. PLGA is a polymer that can be easily processed e.g. solvent casting and thermal processing methods. The 
polymer can cast into any shape using solvents such as chlorinated solvents, tetrahydofuran, acetone and ethyl 
acetate [18, 19]. Understanding the properties of PLGA is important in order to select the right copolymer for this 
study: PLGA is an attractive material and it is a perfect candidate for the fabrication of MN for transdermal use as a 
result of its mechanical, biodegradation and casting characteristics, as it has been shown in recent studies [17]. Chen 
et al. have fabricated successfully MNs patches composed of embeddable chitosan MN and poly(L-lactide-co-D,L-
lactide) (PLA) as a supporting array for the delivery of encapsulated antigens to the skin, being a proper material for 
this purpose [20]. 
3.4. Fabrication process 
A wide range of MN fabrication processes have been researched. These include micro moulding, thermal 
drawing, injection moulding process, centrifugation [3, 21, 22]. In this study, the dissolving MN will be fabricated 
by micro-moulding methods. Moulds are fabricated using a hydrophobic material, PDMS.  The process for 
preparing the moulds involves pouring a PDMS solution over a master structure coated with platinum and then by 
curing the polymer overnight at room temperature. Once moulds are cured, they are peeled from the master 
structures and used as master structures for the creation of MN patches [3]. The polymeric MN will be prepared 
using an atomized spray technique. Recent studies demonstrated that MN can be fabricated with polymeric materials 
creating an amorphous content using single formula sugars, with either a novel laminate-layered or horizontally-
layered dissolving MN arrays, by adapting the spraying method [21]. Polymeric MN have been already fabricated 
by CIT’s research group being orthogonal shaped MN with sharp tips. 
3.5. Sterilisation 
Sterilisation of the prototype is an important consideration. McCrudden et al. studied the considerations in the 
sterile manufacture of hydrogel MN arrays with some model drugs. Results showed that no measurable bioburden 
was detected in any of the prepared devices and endotoxin levels were below the FDA limits (20 endotoxin 
units/device). The hydrogel-forming MN were not affected by gamma irradiation (25 kGy) in terms of their physical 
properties or drug capabilities. However, sterilisation process decreased the drug concentration of the MN patches 
[23]. In this study, the PLGA MN will be sterilised according to the FDA guidelines using gamma radiation. The 
effect of the sterilisation process on the polymer characteristics will be studied and new routes of approach may be 
taken. 
3.6. Applicator design 
To allow a reproducible and repeatable delivery of the drug, MN should be inserted into the skin in a controlled 
and reproducible manner. This demands the use of an applicator such as a manual (thumb pressure actuator or 
applicator system) or mechanical (spring-loaded mechanism or piston driven) system which is either for a single use 
or multiple use [17]. Our research will focus in the design and building of a MN applicator which will be integrated 
into the MN backing layer.  An investigation into the relevant key factors for the clinical use of MN patches (with or 
without applicator) must be considered as these are an important part of the established regulatory requirements, 
these includes [8]: 1) Effective, uniform and repeatable MN application to overcome any variations in skin 
properties; 2) Controlled depth of penetration of the MN into the skin so as to prevent introduction of microbial 
contamination and to avoid potential infections; 3) Sufficient mechanical strength to breach the SC without 
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fracturing the MN structures on the patch; 4) Easy and safe to use as well as being pain-free if an applicator is 
utilised [17]; 5) Ease of sterilisation; and 6) Maintain proper physical stability and physical integrity during storage 
and application. There are several designs commercially available for the use of solid or hollow MN only (3M, 
Zosano® Pharma, MicroCor™, Adminpatch®, Micronjet®, BD Soluvia™, MTS-Rollers™, see in Fig. 3.) but 
commercial applicators for the administration of dissolvable MN are not available at the moment. It has been shown 
that manual impact insertion devices result in low penetration efficiencies (56%) with high inter and intra-individual 
variation compared to mechanical impact insertion devices. This was attributed to the variations in applied force 
which were below optimum insertion conditions [5].  This supports the need for an applicator device to assist in the 
insertion of the MN patch. However, it must also be noted that there are a number of disadvantages associated with 
existing applicators for solid and hollow MN such as: 1) additional application system required by the patch; 2) 
large cumbersome and awkward devices; 3) re-sterilisation for multiple use; 4) risk of infections and 5) clogging of 
MN in the case of hollow MN in its re-use. There are also other designs currently under research that include 
vibration and electrical driven mechanisms [25]. The use of thumb pressure actuation directly onto the base plate of 
the MN patch is complex and with high inter and intra-individual variability. Electrical driven devices which 
possess adjustable forces are more stable over time and more suitable for multiple use compared to manual or spring 
induced forces [25].  However, for single use, a mechanical driven applicator could be better from an economic 
point of view. In the last year, there were publications proving the effective use of integrated systems (built-in 
insertion mechanism into each patch) which are designed with spring loaded mechanism, with two concentric rings, 
and a push-plate, for solid MN with the intended use of penetrating different skin models in one-handling step [2]. 
This proof-of-concept study ascertained that their integrated applicator-assisted insertion method resulted in 80% 
penetration efficiency on a foam material (skin model) compared to manual applicator methods due to the force 
distribution onto the pushing plate and that the puncture efficiency has a factor three times higher when applying 
thumb pressure on the patch base plate directly.  
 
         
Fig 3. MN applicators from different companies. (a) MicroCor™ applicator; (b) Zosano's Macroflux®; (c) AdminPatch®; (d) MicronJet®;         
(e) BD Soluvia™ .Adapted from BD (2009); (f) MTS-Rollers™ applicator. (Adapted for review publication [24]. 
 
The same study also showed that the use of an impact-insertion applicator improves the efficiency and 
reproducibility for a high-density MN path. In this study, spring loaded and push-plate mechanisms will be 
investigated. The applicator and its parts can be fabricated with methods such as 3D printing, plastic injection, or 
with conventional machining, all available in CIT. 
3.7. Characterisation methods 
In order to characterise the fabricated polymeric MN and to set the applicator specifications, the methods used 
will include a qualitative scoring system, imaging using optical light microscopy and scanning electron microscopy 
(SEM) and some methods to determine the physical and structural features of the patches (the shape, size and 
number of micro-needles produced on a patch). Chemical analyses will determine the chemical structure (Raman 
spectroscopy) and the chemical phases present (crystalline/amorphous (differential scanning calorimetry (DSC)). 
The mechanical properties (tensile strength and compression) will be determined using an Instron Dynamic testing 
machine. Also a number of artificial skin models will be examined by using ex-vivo pig skin studies in order to 
understand the influence of MN geometry and applied force versus penetration depth. It is important to note that 
CIT research team in collaboration with UCC have developed expertise in the area of drug delivery, in particular 
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microneedle systems, as well as established effective analytical skills in analysing micro-systems and their 
performance in in-vitro and ex-vivo settings [26]. 
3.8. Modelling 
The information from the skin studies in literature will provide the basic knowledge about micro properties of 
skin that can be used in simulations to assess the parameters of MN geometry that underpin insertion. This 
modelling will be performed using Abaqus FEA software.  By simulating the behaviour of a MN patch insertion in a 
skin model, a greater understanding of the insertion parameters will be ascertained. This understanding will provide 
meaningful information in order to create a feasible applicator integrating both MN patch and MN applicator for 
enhancing user application and, ensuring an effective insertion. Using a virtual model of the skin together with a 
model of MN and applying the rate-dependent out-of-plane hyperplastic properties of the SC and dermis layers, it 
will be possible to establish the optimum parameters for the design of the MN applicator (insertion parameters, 
needle array parameters, such as array density, base plate diameter versus array area, insertion force). This approach 
of predicting the response of a model is cost-effective and time-saving [13] Some studies have already shown 
through modelling, that hyperestatic moduli from a micro-indentation of individual skin strata is rate-dependent, 
which enables extrapolation of stiffness properties for high velocities (greater than 1m/s) and the characteristic 
fracture energies can be lower than the reported values in previous studies (10 pJ/μm2 against >100 pJ/μm2). Also, 
it showed that at higher velocities (around 10 m/s) the energy accumulated in the top skin layers causes fracture 
before stress waves transmit any deformation to the material. It is important to highlight that penetration energy is 
proportional to the skin inflammation, tolerability and acceptability related to the MN insertion. [13]. 
3.9. Clinical compliance 
One of the key objectives of the project is to design an applicator with certain settings so as to enhance usability. 
Norman et al. performed a clinical study that investigated the pain threshold associated with a patch application 
against intramuscular injection, the results showed that patients rated the patches 1.5 on average while the injection 
was rated 15, on a scale one in 100 [4]. The same study also proved that there was increased usability and patient 
acceptability for solid microneedle patches with an applicator. Other clinical studies showed that the use of MN 
technology was positive however there was much concern over the variability involved with the application [27]. 
Finally, a study performed so as to compare the pain and sensory response between silicon microneedle patches and 
single-blinded insertions of a hypodermic needle demonstrated that the MN caused significantly less pain and were 
more comfortable than the hypodermic needles [28]. 
4. Conclusions 
A preliminary literature review and project review has been performed. PLGA is an attractive material with high 
possibilities for the fabrication of MN structures. There is a huge potential market for the use of MN patches as a 
drug delivery system which offers solutions to problems associated with the conventional routes. The proposed 
design after performing this study is a single use, disposal MN patch with an integrated applicator to meet the needs 
of the end-user and to enhance its application. 
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microneedle systems, as well as established effective analytical skills in analysing micro-systems and their 
performance in in-vitro and ex-vivo settings [26]. 
3.8. Modelling 
The information from the skin studies in literature will provide the basic knowledge about micro properties of 
skin that can be used in simulations to assess the parameters of MN geometry that underpin insertion. This 
modelling will be performed using Abaqus FEA software.  By simulating the behaviour of a MN patch insertion in a 
skin model, a greater understanding of the insertion parameters will be ascertained. This understanding will provide 
meaningful information in order to create a feasible applicator integrating both MN patch and MN applicator for 
enhancing user application and, ensuring an effective insertion. Using a virtual model of the skin together with a 
model of MN and applying the rate-dependent out-of-plane hyperplastic properties of the SC and dermis layers, it 
will be possible to establish the optimum parameters for the design of the MN applicator (insertion parameters, 
needle array parameters, such as array density, base plate diameter versus array area, insertion force). This approach 
of predicting the response of a model is cost-effective and time-saving [13] Some studies have already shown 
through modelling, that hyperestatic moduli from a micro-indentation of individual skin strata is rate-dependent, 
which enables extrapolation of stiffness properties for high velocities (greater than 1m/s) and the characteristic 
fracture energies can be lower than the reported values in previous studies (10 pJ/μm2 against >100 pJ/μm2). Also, 
it showed that at higher velocities (around 10 m/s) the energy accumulated in the top skin layers causes fracture 
before stress waves transmit any deformation to the material. It is important to highlight that penetration energy is 
proportional to the skin inflammation, tolerability and acceptability related to the MN insertion. [13]. 
3.9. Clinical compliance 
One of the key objectives of the project is to design an applicator with certain settings so as to enhance usability. 
Norman et al. performed a clinical study that investigated the pain threshold associated with a patch application 
against intramuscular injection, the results showed that patients rated the patches 1.5 on average while the injection 
was rated 15, on a scale one in 100 [4]. The same study also proved that there was increased usability and patient 
acceptability for solid microneedle patches with an applicator. Other clinical studies showed that the use of MN 
technology was positive however there was much concern over the variability involved with the application [27]. 
Finally, a study performed so as to compare the pain and sensory response between silicon microneedle patches and 
single-blinded insertions of a hypodermic needle demonstrated that the MN caused significantly less pain and were 
more comfortable than the hypodermic needles [28]. 
4. Conclusions 
A preliminary literature review and project review has been performed. PLGA is an attractive material with high 
possibilities for the fabrication of MN structures. There is a huge potential market for the use of MN patches as a 
drug delivery system which offers solutions to problems associated with the conventional routes. The proposed 
design after performing this study is a single use, disposal MN patch with an integrated applicator to meet the needs 
of the end-user and to enhance its application. 
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